Illumina
ILMN
$120.37
-5.16%
Illumina Inc. is a global leader in the healthcare sector, specifically within the Medical - Diagnostics & Research industry, providing tools and services to analyze genetic material for life science and clinical lab applications. The company is the dominant market leader in DNA sequencing technology, generating over 90% of its revenue from sequencing instruments, consumables, and services, which positions it as the essential infrastructure provider for genomics research and clinical diagnostics. The current investor narrative is focused on the company's recovery and strategic repositioning following a period of significant challenges, including the costly and ultimately reversed acquisition of GRAIL, with recent attention on its return to core profitability, margin expansion, and the long-term growth trajectory of the genomics market.…
ILMN
Illumina
$120.37
Investment Opinion: Should I buy ILMN Today?
Rating & Thesis: Hold. Illumina is a high-quality company in the midst of a successful operational turnaround, but its current valuation already reflects much of this recovery, leaving limited margin of safety given its modest growth trajectory. The mixed analyst sentiment (Buys, Holds, and an Underweight) underscores this balanced, wait-and-see outlook.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The forward P/E of 22.0x is at a premium, justified by strong profitability (28.8% net margin) but challenged by slow growth (5% YoY revenue). 2) Robust free cash flow generation of $939M TTM provides financial flexibility. 3) The stock trades at 82% of its 52-week range, suggesting limited near-term upside to the $155.53 resistance. 4) High volatility (beta 1.49) increases the risk profile, making timing critical.
Risks & Conditions: The two biggest risks are growth deceleration below 5% and multiple compression in a risk-off market. This Hold would upgrade to a Buy if revenue growth accelerates sustainably above 10% YoY or if the forward P/E compresses below 18x on non-fundamental weakness. It would downgrade to a Sell if quarterly revenue growth turns negative or if operating margins contract significantly below 15%. The stock is currently fairly valued to slightly overvalued relative to its near-term growth prospects, demanding a premium for its quality and market position that may not be sustained without faster top-line expansion.
Sign up to view all
ILMN 12-Month Price Forecast
The outlook for ILMN is one of stabilization rather than breakout. The company has fixed its profitability problem, but the growth engine is not yet firing on all cylinders. The base case of range-bound trading is most probable, as the market digests the turnaround and waits for proof of faster top-line expansion. The stance is neutral due to the balanced risk/reward at current levels; the stock offers quality but at a full price. An upgrade to bullish would require consistent quarterly revenue beats and guidance raises, while a downgrade to bearish would be triggered by margin erosion or a loss of market share.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $156.48 and implied upside of +30.0% versus the current price.
Average Target
$156.48
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$96 - $156
Analyst target range
Analyst coverage for Illumina appears limited, with only 8 analysts providing estimates for future EPS and revenue, indicating this large-cap stock may have reduced Wall Street attention following its recent challenges. The provided data includes consensus estimates for EPS ($8.23) and revenue ($5.68 billion) but does not contain a consensus price target, Buy/Hold/Sell distribution, or target price range, which is insufficient to calculate implied upside or characterize sentiment. Given the lack of explicit target price data, the analyst coverage picture is incomplete; the available institutional ratings from early 2026 show a mix of Buy (Guggenheim, Stifel), Hold (Canaccord, TD Cowen, JP Morgan), and Underweight (Barclays) actions, suggesting a lack of strong consensus and reflecting the ongoing debate about the company's turnaround prospects and valuation.
Bulls vs Bears: ILMN Investment Factors
The bull case, anchored by Illumina's return to strong profitability and cash generation, currently holds stronger evidence than the bear case, which focuses on sluggish growth and a premium valuation. The most critical tension in the investment debate is whether the company's restored bottom-line strength and market dominance can justify its premium multiples in the face of only modest top-line expansion. The resolution of this growth-versus-valuation question will determine if the stock re-rates higher or experiences further compression.
Bullish
- Strong Return to Profitability: Q4 2025 net income of $334 million and a net margin of 28.8% demonstrate a decisive recovery from the massive $1.99 billion loss in Q2 2024. The operating margin expanded to 22.1% in Q4, indicating effective cost control and a return to core operational strength.
- Robust Cash Flow Generation: The company generated $939 million in trailing twelve-month free cash flow, providing ample internal funding for R&D and strategic initiatives without reliance on external capital. This strong cash position supports the turnaround narrative and financial stability.
- Dominant Market Leadership: Over 90% of revenue comes from sequencing, where Illumina is the global infrastructure leader. This entrenched position in the high-growth genomics market provides a durable competitive moat and recurring revenue from consumables and services.
- Healthy Balance Sheet Metrics: A current ratio of 2.08 and a debt-to-equity ratio of 0.94 indicate a solid liquidity position and manageable leverage. This financial health reduces near-term solvency risk and provides flexibility.
Bearish
- Sluggish Top-Line Growth: Q4 2025 revenue grew only 5.0% year-over-year, a modest pace for a supposed growth company in a high-potential market. Sequential quarterly revenue growth from Q1 to Q4 2025 shows a steady but unspectacular recovery trajectory.
- High Volatility and Recent Underperformance: With a beta of 1.49, the stock is 50% more volatile than the market, amplifying downside risk. This is evidenced by a -14.9% return over the past 3 months and a -18.5% relative strength versus the SPY, signaling significant recent selling pressure.
- Premium Valuation Relative to Growth: A trailing P/E of 24.2x and a P/S of 4.7x command a premium, which may not be justified by the current ~5% revenue growth rate. The negative PEG ratio of -0.14 further highlights a disconnect between valuation and expected growth.
- Lack of Strong Analyst Consensus: Only 8 analysts provide estimates, and recent institutional actions show a mix of Buy, Hold, and Underweight ratings. The absence of a clear consensus price target suggests ongoing debate and uncertainty about the turnaround's sustainability.
ILMN Technical Analysis
The stock is in a pronounced long-term uptrend, evidenced by a substantial 64.77% gain over the past year. As of the latest close at $127.88, the price is trading at approximately 82% of its 52-week range ($73.86 to $155.53), indicating it is closer to yearly highs than lows, which reflects strong investor optimism but also suggests potential vulnerability to overextension. However, recent momentum has diverged sharply from this long-term strength, with the stock down 14.91% over the last three months and up a modest 1.33% over the past month, signaling a significant deceleration and a corrective phase within the broader uptrend. This short-term weakness is further highlighted by a negative 3-month relative strength of -18.50% versus the SPY, indicating pronounced underperformance. Key technical levels are clearly defined by the 52-week high of $155.53 as major resistance and the 52-week low of $73.86 as major support; a decisive breakout above resistance would confirm a resumption of the primary bull trend, while a breakdown below recent lows near $115 could signal a deeper correction. The stock's beta of 1.49 confirms it is approximately 50% more volatile than the broader market, which amplifies both upside potential and downside risk, a critical factor for risk management.
Beta
1.49
1.49x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$74-$156
Price range past year
Annual Return
+56.1%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | -0.4% | +12.6% |
| 3m | -19.6% | +2.5% |
| 6m | -2.6% | +4.3% |
| 1y | +56.1% | +28.4% |
| ytd | -10.4% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $1.159 billion representing a 4.98% year-over-year increase; sequentially, revenue has grown from $1.041 billion in Q1 to the Q4 level, indicating a steady, albeit not explosive, recovery trajectory. The business is heavily driven by its core Sequencing segment, which contributed $1.065 billion in the latest period, dwarfing the Microarray segment's $94 million. The company has returned to solid profitability, posting net income of $334 million in Q4 2025, with a robust gross margin of 67.04% and an operating margin of 22.09%; these margins represent a significant expansion from the depressed and volatile levels seen in 2024, particularly the disastrous Q2 2024 which featured a net loss of nearly $2 billion. The balance sheet and cash flow position are healthy, with a strong current ratio of 2.08, a manageable debt-to-equity ratio of 0.94, and the generation of substantial free cash flow, evidenced by a trailing twelve-month figure of $939 million, which provides ample internal funding for operations and strategic initiatives.
Quarterly Revenue
$1.2B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$939000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 24.2x, while the forward PE is slightly lower at 22.0x; this modest discount in the forward multiple suggests the market anticipates only a slight improvement in earnings growth. Compared to sector averages (data not explicitly provided in the input, but typical for the industry), a trailing PE in the mid-20s is generally at or above the healthcare equipment sector average, implying Illumina trades at a premium, which may be justified by its market-leading position and recovery narrative. Historically, the stock's own valuation has normalized from extreme levels; the current trailing PE of 24.2x is significantly below the 28.4x seen at the end of 2024 and far more reasonable than the negative or triple-digit PEs during its loss-making periods in 2023-2024, suggesting the market has repriced the stock to reflect its regained, stable profitability.
PE
24.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -56x~2943x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not solvency—given the strong current ratio and free cash flow—but rather growth stagnation. Revenue growth of just 5% YoY is insufficient to support a premium valuation if it persists, potentially leading to multiple compression. Furthermore, the company's heavy reliance on its Sequencing segment (~92% of revenue) creates concentration risk; any technological disruption or pricing pressure in this core market would have an outsized impact. While margins have recovered impressively, maintaining a ~67% gross margin and >20% operating margin requires continuous operational discipline in a competitive landscape.
Market & Competitive Risks: The stock's high beta of 1.49 makes it highly sensitive to broader market swings, particularly detrimental in risk-off environments as seen in the recent 3-month underperformance. Trading at a forward P/E of 22x, it carries valuation compression risk if growth stock multiples contract or if earnings fail to meet the implied growth expectations. Competitively, while Illumina is the incumbent leader, the genomics tools market is attractive and could draw increased competition, potentially eroding pricing power and market share over the long term.
Worst-Case Scenario: The worst-case scenario involves a combination of failed growth acceleration and a broader market sell-off targeting expensive stocks. This could trigger analyst downgrades, multiple compression from the current ~24x P/E toward the sector average (likely in the high teens), and a retest of the 52-week low of $73.86. A realistic adverse scenario could see the stock decline -35% to -40% from the current price, revisiting the $80-$90 range, driven by disappointing earnings, lowered guidance, and a shift in investor sentiment away from premium-priced turnarounds.
FAQ
The key risks are: 1) Growth Stagnation: The most severe risk is that revenue growth remains in the low-to-mid single digits (currently 5% YoY), failing to support the premium valuation. 2) Market Volatility: With a beta of 1.49, ILMN is highly sensitive to market swings, as seen in its -18.5% relative underperformance over the past 3 months. 3) Competitive Disruption: While the incumbent, the genomics tools market is attractive and could face increased competition over time, potentially pressuring pricing and margins. 4) Execution Missteps: Any failure to maintain the recovered profitability (22% operating margin) or to successfully launch new products could damage the turnaround narrative.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $125 and $145, as steady execution and maintained profitability lead to range-bound action. The Bull Case (25% probability) targets $155 to $170, driven by accelerated revenue growth and multiple expansion. The Bear Case (15% probability) warns of a decline to $85-$105 if growth stalls and the premium multiple compresses in a risk-off market. The Base Case is most likely, predicated on the assumption that the current recovery stabilizes without a significant growth breakout in the near term.
ILMN appears fairly valued to slightly overvalued based on its current growth profile. The trailing P/E of 24.2x and forward P/E of 22.0x command a premium, which is partially justified by its strong net margin of 28.8% and market leadership. However, this premium is challenged by modest revenue growth of ~5% YoY. Compared to typical healthcare equipment peers, its multiples are at the higher end. The valuation implies the market is paying for quality and a recovery narrative, expecting future growth to accelerate to justify the price. Without that acceleration, the stock is vulnerable to multiple compression.
ILMN is a good buy for investors seeking a high-quality, market-leading company that has successfully navigated a major turnaround, but it is not without risk. At a forward P/E of 22x and with only 5% revenue growth, the valuation is full, leaving little room for error. The strong profitability, robust cash flow, and dominant market position are positives, but the high stock volatility (beta 1.49) and recent underperformance warrant caution. It is a good buy for long-term believers in genomics who can tolerate volatility and are comfortable with a 'Hold' rating in the near term, awaiting clearer growth acceleration.
ILMN is more suitable for a long-term investment horizon of 3-5 years rather than short-term trading. Its high beta of 1.49 makes it prone to sharp swings, which can punish short-term traders. As a turnaround story in a secular growth market (genomics), the full value of the recovery and subsequent growth phase may take years to materialize. The company does not pay a dividend, so returns are solely based on capital appreciation. Investors should be prepared to hold through volatility to capture the long-term potential of genomics adoption. A minimum holding period of 18-24 months is suggested to evaluate the success of the growth acceleration thesis.